MInimal Residual Disease Adapted Strategy
MInimal Residual Disease Adapted Strategy
Active, not recruiting · NCT04934475 · Registry updated 2024-11-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MInimal Residual Disease Adapted Strategy | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2024-11-07 | NCT04934475 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amgen | 180 |
| Bristol-Myers Squibb | 422 |
| Intergroupe Francophone du Myelome | 7 |
| Sanofi | 254 |
73 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.